Zydus Wellness Ltd share price logo

Zydus Wellness Ltd (ZYDUSWELL)

₹2140.61.7%

bell
Get free price alerts. Set up your Free investment account to get Live Prices.
Overview
News
Financials
Q3 '23 Results
Technicals

Analyst Rating

based on 5 analysts

BUY

83.33%

Buy

16.67%

Hold

0.00%

Sell

Based on 5 analysts offering long term price targets for Zydus Wellness Ltd. An average target of ₹1947.2

Source: S&P Global Market Intelligence

Zydus Wellness Ltd Share analysis

Source: S&P Global Market Intelligence

Performance

  • Day's Low

    Day's High

    ₹2,125.85
    ₹2,175
  • 52 Week's Low

    52 Week's High

    ₹1,425.05
    ₹2,217.55
1 Month Return+ 17.95 %
3 Month Return+ 35.58 %
1 Year Return+ 48.18 %
Previous Close₹2,177.55
Open₹2,152.05
Volume22.60K
Upper Circuit-
Lower Circuit-
Market Cap₹13,856.22Cr

Key Statistics

P/E Ratio51.91
PEG Ratio-7.61
Market Cap₹13,856.22 Cr
P/B Ratio2.32
EPS41.97

Mutual Fund Holdings

Funds HoldingsPrev. 6M
Nippon India Small Cap Fund - Direct Plan - Growth PlanNippon India Small Cap Fund - Direct Plan - Growth Plan0.7%
SBI Small Cap Fund Direct Plan GrowthSBI Small Cap Fund Direct Plan Growth0.81%
ICICI Prudential Value Discovery Fund Direct Plan GrowthICICI Prudential Value Discovery Fund Direct Plan Growth0.31%
ICICI Prudential Multicap Fund Direct Plan GrowthICICI Prudential Multicap Fund Direct Plan Growth0.31%
Nippon India Balanced Advantage Fund Direct Growth PlanNippon India Balanced Advantage Fund Direct Growth Plan0.38%

Company Information

Headquartered in Ahmedabad, Zydus Wellness operates as an integrated consumer company with a portfolio of well-known health and wellness brands including GluconD, Complan, Sugar Free, Nycil, Everyuth, Nutralite, and Sugarlite. To facilitate its distribution across India, the Company has invested in 24 integrated warehouses, 1,700 distributors and 2,000 feet-on-street representatives. It has established five manufacturing operations and its flagship portfolio has maintained leadership across respective categories. Despite the pandemic-induced setbacks, the Company launched 11 new products in FY2021-22. These include GluconD ImmunoVolt, ImmunoFizz, Complan, Nutralite Professional Range, Everyuth New Body Lotion Range, Nutralite DoodhShakti Professional Pure Ghee & Butter, Sugar Free DLite Cookies, Sugar Free DLite Chocolate Spread, and more. It has also expanded its international footprint by entering new geographies, such as Hong Kong, Lebanon, Zimbabwe, Muscat, Ethiopia and Australia. The Company inaugurated a new RD set-up in Ahmedabad in 2021-22 and also incorporated a new company, Zydus Wellness BD Pvt Limited, as a wholly-owned subsidiary in Bangladesh.

Share Price: ₹2140.60 per share as on 15 Jul, 2024 04:01 PM
Market Capitalisation: ₹13,856.22Cr as of today
Revenue: ₹778.00Cr as on March 2024 (Q1 24)
Net Profit: ₹150.30Cr as on March 2024 (Q1 24)
Listing date: 13 Nov, 2009
Chairperson Name: Sharvil P Patel
OrganisationZydus Wellness Ltd
HeadquartersAhmedabad
IndustryFMCG
E-voting on sharesClick here to vote

Key events for Zydus Wellness Ltd

  • Zydus Wellness Ltd's High P/E Ratio Raises Concerns - 12 Jul, 2024

    Zydus Wellness Ltd's P/E ratio of 51.8x is significantly higher than the market average, despite its recent earnings decline. Analysts predict a 22% EPS growth rate over the next three years, but investors may be overvaluing the stock.

  • Zydus Receives FDA Approvals for Two Drugs - 11 Jul, 2024

    Zydus Wellness Ltd received FDA approvals for two drugs - diroximel fumarate delayed-release capsules for multiple sclerosis and sacubitril and valsartan tablets for chronic heart failure. However, the Delhi High Court issued an injunction against the sale of its breast cancer drug, causing a drop in share prices.

  • Zydus Lifesciences Receives FDA Approvals for Two Drugs - 10 Jul, 2024

    Zydus Wellness subsidiary, Zydus Lifesciences, has received final approval from the USFDA to market a generic drug for treating chronic heart failure and tentative approval for a drug to treat multiple sclerosis.

  • Zydus Receives Tentative Approval for Hypertension Drug in the US - 04 Jul, 2024

    Zydus Wellness subsidiary, Zydus Lifesciences, has received tentative approval from the US Food and Drug Administration (USFDA) to market its generic Azilsartan Medoxomil tablets used to treat high blood pressure. The drug had annual sales of USD 89 million in the US.

  • Zydus Subsidiary Receives Income Tax Notice Demand - 02 Jul, 2024

    Zydus Wellness' wholly-owned subsidiary, Zydus Healthcare, has received an income tax notice demand of Rs 284.58 crore for the assessment year 2023-24.

  • Zydus Enters Licensing Agreement for Breast Cancer Drug - 01 Jul, 2024

    Zydus Wellness has entered into a licensing agreement with Dr. Reddys Laboratories to co-market Pertuzumab biosimilar, a critical drug for HER2 positive breast cancer patients in India.

  • Zydus Wellness Stock Shows Strong Base Formation - 30 Jun, 2024

    Long-term investors can buy Zydus Wellness at current levels as the stock has consolidated above Rs 1,500 and formed a strong base. The recent rise in share price is significant with clear signs of bottom formation, indicating the end of downtrend since October 2021. Moving average cross overs on short-term chart strengthen bullish case. Potential to take Zydus Wellness share price up to Rs 3,000-3,200 over next couple of years.

  • Zydus Cadila to Co-Market Biosimilar for Breast Cancer Treatment - 28 Jun, 2024

    Zydus Cadila has entered into a licensing agreement with Dr. Reddy's Laboratories to co-market Pertuzumab biosimilar in India, which is used to treat HER2 positive breast cancer patients.

  • Zydus Wellness Ltd Recommends Dividend of Rs. 5 per Share - 21 Jun, 2024

    The Board of Directors of Zydus Wellness Ltd has recommended a dividend of Rs. 5 per equity share for the year ended March 31, 2012.

  • Zydus Wellness to Pay Dividend of ₹5.00 per Share - 15 Jun, 2024

    Zydus Wellness Limited will pay a dividend of ₹5.00 per share on March 9th, with a yield of 0.3%. The company's earnings per share are forecasted to rise by 83.6% over the next year, and assuming recent trends continue, the payout ratio could be sustainable at 6.5% next year.

  • Zydus Lifesciences Receives Tentative Approval for Blood Pressure Drug in the US - 14 Jun, 2024

    Zydus Wellness subsidiary, Zydus Lifesciences, has received tentative approval from the US FDA to market Azilsartan Medoxomil and Chlorthalidone tablets for high blood pressure. The drug had annual sales of $77.9 million in the US according to IQVIA MAT data from March 2024.

Insights on Zydus Wellness Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, ZYDUSWELL has outperformed top 5 stocks with highest market-cap in Food Processing

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 8.25% to 8.38% in Jun 2024 quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, 0.3 Cr → 150.3 Cr (in ₹), with an average increase of 99.8% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 406.6 Cr → 786.6 Cr (in ₹), with an average increase of 48.3% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, ZYDUSWELL stock has moved up by 5.4%

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 3.26% to 3.29% in Jun 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Britannia Industries Ltd has given 67.2% return, outperforming this stock by 70.0%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 69.62% of holdings in Jun 2024 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 7.71% to 7.65% in Jun 2024 quarter

Company Financials

Value in ₹ crore
Q'1 24Q/Q Change
Revenue
₹778.00Cr
↑94.45%
Net Income
₹150.30Cr
↑50,000.00%
Net Profit Margin
19.32%
↑27,500.00%
2024Y/Y Change
Revenue
₹2,327.80Cr
↑3.24%
Net Income
₹266.90Cr
↓14.01%
Net Profit Margin
11.47%
↓16.70%
Value in ₹ crore
2024Y/Y Change
Total Assets
₹4,116.80Cr
↑1.21%
Total Liabilities
₹80.90Cr
↑143.67%
Value in ₹ crore
2024Y/Y Change
Operating Cash Flow
₹26.00Cr
↓29.16%

Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
69.62%
0.00
Foreign Institutions
3.29%
1.05
Mutual Funds
8.38%
1.56
Retail Investors
7.65%
-0.81
Others
11.06%
-0.90

Key Indicators

Zydus Wellness Ltd Valuation

Zydus Wellness Ltd in the last 5 years

  • Overview

  • Trends

Lowest (26.94x)

July 9, 2019

Today (51.91x)

July 12, 2024

Industry (67.85x)

July 12, 2024

Highest (224.26x)

January 4, 2021

LowHigh

Earnings and Dividends

  • Zydus Wellness Ltd Earnings Results

    Zydus Wellness Ltd’s net profit jumped 3.44% since last year same period to ₹150.30Cr in the Q4 2023-2024. On a quarterly growth basis, Zydus Wellness Ltd has generated 50000% jump in its net profits since last 3-months.

    Read More about Earnings Results
  • Zydus Wellness Ltd Dividends May,2024

    In the quarter ending March 2024, Zydus Wellness Ltd has declared dividend of ₹5 - translating a dividend yield of 0.46%.

    Read More about Dividends

Technicals Summary

Bearish

Neutral

Bullish

Bullish

Zydus Wellness Ltd is currently in a Bullish trading position according to technical analysis indicators.

Frequently Asked Questions

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Zydus Wellness Ltd shares.

Zydus Wellness Ltd (ZYDUSWELL) share price today is ₹2140.6

Zydus Wellness Ltd is listed on NSE

Zydus Wellness Ltd is listed on BSE

  • Today’s highest price of Zydus Wellness Ltd is ₹2175.
  • Today’s lowest price of Zydus Wellness Ltd is ₹2125.85.

PE Ratio of Zydus Wellness Ltd is 51.91

PE ratio = Zydus Wellness Ltd Market price per share / Zydus Wellness Ltd Earnings per share

Today’s traded volume of Zydus Wellness Ltd(ZYDUSWELL) is 22.60K.

Today’s market capitalisation of Zydus Wellness Ltd(ZYDUSWELL) is ₹13856.22Cr.

Zydus Wellness Ltd(ZYDUSWELLPrice
52 Week High
₹2217.55
52 Week Low
₹1425.05

Zydus Wellness Ltd(ZYDUSWELL) share price is ₹2140.6. It is down -3.47% from its 52 Week High price of ₹2217.55

Zydus Wellness Ltd(ZYDUSWELL) share price is ₹2140.6. It is up 50.21% from its 52 Week Low price of ₹1425.05

Zydus Wellness Ltd(ZYDUSWELLReturns
1 Day Returns
-36.95%
1 Month Returns
17.95%
3 Month Returns
35.58%
1 Year Returns
48.18%